A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01812746
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
CRPC
Prostate Cancer
Interventions
DRUG:
BIND-014
Sponsor
BIND Therapeutics